ABSTRACT
Palladium-103 (103Pd) and iodine-125 (125I) are the most commonly used radioisotopes for permanent prostate brachytherapy. The choice of palladium versus iodine is typically based on physician preference, although it is sometimes driven by the patient. While the controversy continues regarding which is the superior source, palladium has long been my isotope of choice, a preference that dates back to my experience with both 103Pd and 125I at New York University Medical Center and Memorial SloanKettering in the mid 1980s. My research and clinical practice in Tampa during the following decade and my more recent Sarasota experience have confirmed the advantage of 103Pd even for low grade prostate malignancies.
